StockIQ.techRoyalty Pharma plc (RPRX) Stock Analysis
Free AI-powered analysis and research for Royalty Pharma plc stock
Sector: Healthcare
RPRX snapshot
Data as of 3 Nov 2026 close. Updated daily.
Royalty Pharma plc scores 100/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 98% of its 52-week range, up 80.2% over the past year. Latest reported figures show a profit margin of 32.0%, return on equity of 14.0% and revenue growth of +16.5%.
What is driving the score
- Strong Uptrend: +12
- MACD Bullish: +8
- High P/E (34.7): -10
- Strong Revenue Growth (16.5%): +8
- Excellent Profit Margin (32.0%): +10
- Strong Liquidity (2.80 Current Ratio): +8
- Strong Long-term Uptrend: +8
- Strong Rise (+80.2% over 1 year): +10
- Low Volume (0.3x): -3
- Near 52-Week High (98%): +5
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full RPRX report
Royalty Pharma plc (RPRX) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze RPRX Now →📰 Latest Update
Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics
Fri, October 30, 2026 at 12:15 PM UTC 2 min read
Royalty Pharma (RPRX) has released its Q3 outlook, with Wall Street projecting key metrics that indicate continued growth potential. Analysts are particularly focused on revenue expectations and earnings per share, which could influence investor sentiment and stock performance. This outlook is crucial for investors as it provides insights into the company's financial health and future prospects in the biopharmaceutical sector.